Dallas, TX -- (SBWire) -- 03/12/2015 --The report "Streptococcus Pyogenes Infections – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections. Streptococci are bacteria that are commonly found harmlessly living in the human respiratory, gut and genitourinary systems. Several species are capable of causing disease in humans, including skin diseases. Skin diseases due to direct infection with streptococcus include: Impetigo, Ecthyma, Cellulitis, Erysipelas, Necrotising fasciitis, Secondary skin infection of wounds, dermatitis, scabies, diabetic ulcers, Tropical ulcers, Blistering distal dactylitis, Streptococcal perianal and vulval dermatitis. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/streptococcus-pyogenes-infections-pipeline-review-h1-2015-market-report.html.
This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects.
Companies discussed in this report include:
- Absynth Biologics Limited
- GlycoVaxyn AG
- Helix BioMedix, Inc.
- Novartis AG
- Sumitomo Dainippon Pharma Co., Ltd.
- Wellstat Vaccines, LLC
Drugs profiled discussed in this report include HB-1345, SM-295291, SM-369926, Small Molecules to Inhibit DHFR for Infectious Diseases, streptococcus [serotype A] vaccine, streptococcus [serotype A] vaccine, streptococcus pyogenes vaccine, streptococcus pyogenes vaccine, streptococcus pyogenes vaccine (30-valent). Order a copy of this report at (Prices start at US $ 2000 for a single user PDF) http://www.rnrmarketresearch.com/contacts/purchase?rname=310152 .
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
List of Tables
Number of Products under Development for Streptococcus Pyogenes Infections, H1 2015 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Streptococcus Pyogenes Infections - Pipeline by Absynth Biologics Limited, H1 2015 14
Streptococcus Pyogenes Infections - Pipeline by GlycoVaxyn AG, H1 2015 15
Streptococcus Pyogenes Infections - Pipeline by Helix BioMedix, Inc., H1 2015 16
Streptococcus Pyogenes Infections - Pipeline by Novartis AG, H1 2015 17
Streptococcus Pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 18
Streptococcus Pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Streptococcus Pyogenes Infections Therapeutics - Recent Pipeline Updates, H1 2015 39
Streptococcus Pyogenes Infections - Dormant Projects, H1 2015 40
List of Figures
Number of Products under Development for Streptococcus Pyogenes Infections, H1 2015 7
Number of Products under Development for Streptococcus Pyogenes Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27
Explore more reports on Allergy Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/allergy-drugs.
Streptococcus Pyogenes Infections Therapeutic Pipeline H1 2015 Market Review Research Report